Quantitative proteomics analysis to identify biomarkers of refractory benign paroxysmal positional vertigo

TL;DR

This study uses proteomics to find biomarkers for refractory BPPV, linking them to cholesterol and platelet processes.

Contribution

First TMT-based proteomics study on refractory BPPV, identifying 57 potential biomarkers.

Findings

Identified 57 differentially expressed proteins in refractory BPPV patients.

Linked BPPV mechanisms to cholesterol metabolism and platelet activation.

Confirmed five potential biomarker proteins using parallel reaction monitoring.

Abstract

•This is the first TMT-based proteomics study on refractory BPPV.•57 potential biomarkers identified significant for improving diagnostic accuracy.•BPPV mechanisms are related to cholesterol metabolism and platelet activation.

This is the first TMT-based proteomics study on refractory BPPV.

57 potential biomarkers identified significant for improving diagnostic accuracy.

BPPV mechanisms are related to cholesterol metabolism and platelet activation.

Benign Paroxysmal Positional Vertigo (BPPV) is transient vertigo and paroxysmal nystagmus induced by changes in head position. This study was conducted to investigate the differential expression of serum proteins in patients with refractory BPPV and to screen for diagnostic biomarkers.

Serum samples were collected from patients with BPPV; tandem mass tag-based quantitative proteomics technology was used to detect and quantify the serum proteins of 30 individuals with refractory BPPV and 30 control volunteers. Bioinformatics analysis of differentially expressed proteins was performed using hierarchical clustering, gene ontology annotation, Kyoto Encyclopedia of Genes and Genomes analysis, and protein-protein interaction network analysis.

A total of 769 proteins were identified, and 57 differentially expressed proteins were screened between the two groups; 15 proteins were upregulated, whereas 42 were downregulated. Five differentially expressed proteins were chosen for parallel reaction monitoring analysis to confirm the results. Apolipoprotein A-I, apolipoprotein A-II, apolipoprotein C-III, fibrinogen gamma chain, and fructose-bisphosphate aldolase B were the five potential candidate biomarker proteins.

This is the first quantitative proteomic study to reveal diagnostic biomarkers in patients with BPPV using tandem mass tag labeling technology. The identified differential proteins may improve the understanding of the pathogenesis and molecular mechanism of BPPV.

Level 4.

Figures